Current and Future Trends in Treatment of Severe Retinopathy of Prematurity

David K. Wallace, Katherine Y. Wu

Research output: Contribution to journalReview article

18 Scopus citations

Abstract

Treatment for retinopathy of prematurity (ROP) is indicated when type 1 disease is present. The Early Treatment for Retinopathy of Prematurity (ETROP) clinical trial established that laser treatment of severe ROP has a high rate of visual and anatomic success. Recently, anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab have been used in lieu of or in addition to laser treatment. Results are promising, but long-term outcomes and systemic side effects are unknown. Future studies are needed to determine whether anti-VEGF treatment is superior to laser and, if so, which drug and dose are safe and effective.

Original languageEnglish (US)
Pages (from-to)297-310
Number of pages14
JournalClinics in Perinatology
Volume40
Issue number2
DOIs
StatePublished - Jun 1 2013

    Fingerprint

Keywords

  • Bevacizumab
  • Clinical trials
  • Laser photocoagulation
  • Retinopathy of prematurity
  • Side effects
  • Type 1

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this